Definiens Strengthens Position as Global Service Provider in Biopharma
Jacques Corriveau joining as General Manager North America
November 13, 2017 (Newswire.com) -
Definiens, the leader in Tissue
Phenomics® announced the strengthening of its global commercial leadership team by appointing Jacques Corriveau as Vice President and General Manager North America. This addition will support the company’s strategic shift and further growth as an end-to-end transformative service provider for biomarker programs in immuno-oncology.
Jacques brings more than 15 years’ experience in commercial leadership within the life science and healthcare market. Before joining Definiens, he held various executive positions developing and executing global go-to-market strategies for disruptive technologies in both research and clinical markets. With this addition, Definiens strengthens its strategic focus and position of its U.S. headquarters in Boston, Massachusetts, a key center of permanent business growth and future expansion in the North American region.
As a service-centric company, Definiens’ recently enhanced services portfolio sets a new milestone for biomarker-dependent drug development in immuno-oncology. Definiens’ unsurpassed offering of biomarker discovery solutions guides preclinical and clinical trial programs in immuno-oncology across the globe, allowing clients to expedite trial programs and to find more predictive biomarkers for new therapies. Definiens’ unique ability to integrate spatial dependencies and multi-omics analytics of immune and tumor cells in a common context, positions Definiens at the forefront of biomarker development - from research and early clinical through companion diagnostics.
Jacques Corriveau commented, “I am thrilled to be part of the Definiens team particularly now as we see the convergence of genomic analysis and tissue image analysis to rapidly expand the pace of personalized medicine. Definiens has the right technology and expertise to significantly reduce time to results in early clinical trials and select the right patients for advanced trials. This ultimately leads to more successful clinical programs. Our goal is to support pharmaceutical companies with biological insights and to help them to not only generate data but come to the right conclusion and decisions for the benefit of cancer patients. We have significantly strengthened our capabilities to provide strong value to customers and patients leveraging Tissue Phenomics®.”
Definiens Chief Commercial officer Michael Rasche added: “We are excited to have Jacques joining our global commercial team. His experience in the immuno-oncology space, combined with his outstanding people leadership skills, are a perfect cultural and strategical fit for Definiens and our ambition to continue our steep growth and team expansion in North America. Our clients, partners and our regional team will equally benefit from his expertise.”
Definiens once again proves its commitment to put an unprecedented team of leading experts in place to drive innovation in immuno-oncology and to being a key partner with expertise to support tissue-based oncology biomarker programs from start to finish.
Improving patient lives by unlocking the tissue phenome
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs in immuno-oncology by helping pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomics® - technology. Our expertise accelerates and deepens understanding of disease biology and immune system mechanisms and allows to bring multi-omics data into a cancer-relevant context, which facilitates the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique and actionable patient profiles through harmonized biomarkers for an individualized standard of care, where patients experience fewer side effects and live longer. Definiens’ proven technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 650 peer-reviewed publications.
Definiens is a member of the AstraZeneca group providing products and services to companies across the life sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.
Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit www.definiens.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data being presented at the 2017 Society for Immunotherapy of Cancer (SITC) held Nov. 10-11, 2017 in National Harbor, Maryland. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements.
+49 (0) 89 231180-00
Source: Definiens AG